Physician profile
Christopher M Byrne
NPI 1306846415
$29,404.85
in general payments reported to CMS, 2019-2025
41 companies · $4,038 in 2025
The $4,038 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,982 · 2022: $6,429 · 2023: $9,026 · 2024: $3,929 · 2025: $4,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $4,825 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,680.24 |
| Consulting Fee | $4,825.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Education | $238.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $5,675.00 | 2022-2023 | Neo-Synalar, Clindacin Etz |
| Janssen Biotech, INC. | $3,420.13 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $3,162.52 | 2021-2025 | Opzelura |
| Abbvie INC. | $3,012.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,099.50 | 2021-2025 | |
| Lilly USA, LLC | $1,391.54 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ani Pharmaceuticals, INC. | $1,250.00 | 2023 | Veregen |
| Leo Pharma INC. | $1,216.01 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $1,214.76 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $873.02 | 2023-2025 | Zoryve |
| Ucb, INC. | $851.44 | 2021-2025 | Bimzelx, Cimzia |
| Almirall LLC | $776.28 | 2021-2025 | Seysara, Klisyri |
| Genzyme Corporation | $593.53 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $571.91 | 2021-2025 | Winlevi |
| Amgen INC. | $476.22 | 2021-2025 | Otezla, Otezla |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.